Therapeutic targeting of the CXCL12–CXCR4 axis using CXCR4 inhibitors weakens the adhesion of MM PCs on the TME, which renders them more sensitive to PI treatment (165). This evidence concerns the gene CXCR4 and Miyoshi myopathy.